Home
Cisplatin

Cisplatin

Name: Cisplatin
Brand: APExBIO
SKU: A8321
Price: 51.00 USD
Availability: InStock

Catalog No.

A8321

A chemotherapeutic drug that inhibits DNA synthesis, commonly used to construct acute kidney injury (AKI) animal models.

Skip to the end of the images gallery

Skip to the beginning of the images gallery

Grouped product items
Size	Price	Stock
100mg	$51.00	In stock
500mg	$130.00	In stock
1g	$206.00	In stock

For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background
Product Citation
Chemical Properties
Protocol
Biological Activity
Quality Control
User Guide

Background

Cisplatin (CAS 15663-27-1) is a potent and broad-spectrum chemotherapeutic agent[1].

Cisplatin is an anticancer agent that induces apoptosis through multiple mechanisms. After entering cells, cisplatin binds to guanine bases of DNA, forming intra- and interstrand crosslinks that block DNA replication, and it can induce apoptosis by activating p53. Cisplatin also generates ROS and increases lipid peroxidation, thereby inducing apoptosis. In addition, cisplatin induces apoptosis through caspase-dependent pathways. In cochlear cells, cisplatin treatment increases caspases-3 and caspases-9, causing ototoxic side effects[1].

Cisplatin also mediates caspase-3-dependent apoptosis through the ERK signaling pathway; its treatment of cochlear cells increases caspase-3 and caspase-9 expression levels, leading to cochlear damage[1].

Cisplatin is commonly used to establish acute kidney injury (AKI) animal models. A single administration induces tubular injury and dysfunction, and it is widely used in studies of nephrotoxicity mechanisms and renoprotective drugs.

References: [1] Casares C, Ramirez-Camacho R, Trinidad A, et al. Reactive oxygen species in apoptosis induced by cisplatin: review of physiopathological mechanisms in animal models. European Archives of Oto-Rhino-Laryngology, 2012, 269(12): 2455-2459.

Product Citation

Hide ↑↑

Chemical Properties

Physical Appearance	A solid
Storage	Desiccate at 4°C away from light It is recommended to store in the form of powder in the dark, the solution is very unstable (Prepare Solution fresh and use at room temperature), DMF is recommended, DMSO can inactivate Cisplatin's activity.
M.Wt	300.05
Cas No.	15663-27-1
Formula	Cl₂H₆N₂Pt
Synonyms	CDDP
Solubility	insoluble in EtOH; insoluble in H2O; ≥12.5 mg/mL in DMF
Chemical Name	azane;dichloroplatinum(2+)
Canonical SMILES	[Cl-]->1.[Cl-]->2.[NH3]->3.[NH3]->4.[Pt+2]1234
Shipping Condition	Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips	We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Cell experiment [1]:
Cell lines	L1210/0 cells
Preparation method	The solubility of this compound in DMF is >12.5 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.
Reaction Conditions	0, 0.5, 1, 2, 4 and 8 μg/mL; 2 hrs
Applications	At low concentrations, Cisplatin induced minimal cell death. At higher concentrations, cell death was obvious with only 4% viability. By 10 days after incubation, these few survivors begun to grow and became the predominant cells in the population.
Animal experiment [2]:
Animal models	Nude mice bearing human ovarian cancer OVCAR-3 cell xenografts
Dosage form	5 mg/kg, i.v.; at day 0 and day 7
Applications	Cisplatin (5 mg/kg) given at the day 0 and 7 induced a tumor growth inhibition (GI) (85.1%) of the OVCAR-3 cell xenografts.
Other notes	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
References: [1]. Sorenson CM, Eastman A. Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res. 1988 Aug 15;48(16):4484-8. [2]. Molthoff CF, Pinedo HM, Schlüper HM, Rutgers DH, Boven E. Comparison of 131I-labelled anti-episialin 139H2 with cisplatin, cyclophosphamide or external-beam radiation for anti-tumor efficacy in human ovarian cancer xenografts. Int J Cancer. 1992 Apr 22;51(1):108-15.